Retatrutide targets three receptors: GIP, GLP-1 and glucagon. It has been the most-hyped molecule in the pipeline for two years, and this site has covered its first-in-human data. Now there is a phase 3 monotherapy result in type 2 diabetes [1].
HbA1c fell 1.69 percentage points on 4 mg, 1.86 on 9 mg and 1.94 on 12 mg. Those are large numbers. But the placebo arm fell 0.81 points over the same 40 weeks, which is unusually large for a placebo, and it changes what the drug can be said to have done.
Weight fell 11.5%, 13.9% and 15.3% across the three doses against 2.6% on placebo, in a population whose average BMI was 35.8 and whose diabetes averaged 2.5 years in duration. These were people early in the disease, not long-standing cases on multiple agents, which is the easiest setting for a glucose drug to look good in.
On safety, discontinuation for adverse events ran 2% to 5% on retatrutide and 0% on placebo, with gastrointestinal events the most common and generally mild to moderate. No severe hypoglycemia was reported. Two deaths occurred during the study, both in the 4 mg group, and the paper describes both as unrelated to the study drug. That is what the record says; it is not evidence of a dose-related hazard, since the two higher doses had none.
Retatrutide is not approved and not sold, a point worth repeating because the name circulates in gray-market listings — this site covered what is not for sale. What this trial establishes is that a third receptor does not obviously break anything at 40 weeks in an easy population. Whether it beats the drugs already on pharmacy shelves is a head-to-head question, and this trial used placebo — the same gap this site keeps finding, as in a trial designed to tie.